JJJuan Jiao

Juan Jiao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juan Jiao has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Yang Li

    Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

    7 shared publications
  • Meijuan Long

    Baoding Hospital affiliated to Guang 'anmen Hospital, Beijing, Hebei, China

    6 shared publications
  • Shiya Wu

    Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

    5 shared publications
  • Yidan Wang

    Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

    5 shared publications
  • Quan Jiang

    4 shared publications
  • Zihao Li

    Rheumatology Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, China

    4 shared publications

Latest Publications

  • Open Access

    Pharmacologic treatment of fibromyalgia: an update

    by Yang Li, Yunshen Li, Shiya Wu, Meijuan Long, Xinyi Chen, Yidan Wang, Jianan Zhao, Bingheng He, Cen Chang, Juan Jiao

    Fibromyalgia (FM) is a chronic pain disorder characterized by widespread musculoskeletal pain, frequently accompanied by fatigue, sleep disturbances, cognitive dysfunction, and mood disorders. Although the etiology is multifactorial, involving genetic, hormonal, immunological, and environmental contributors, the exact pathophysiological mechanisms remain unclear, and the heterogeneity of symptoms poses significant challenges for diagnosis and management. Diagnostic criteria have evolved over the years, with newer approaches reducing some limitations, yet sex-related differences in clinical presentation continue to challenge timely and accurate diagnosis. Pharmacological therapy remains unsatisfactory: only pregabalin, duloxetine, and milnacipran have gained U.S. FDA approval, providing clinically meaningful relief in a minority of patients, and their frequent adverse events limit adherence. Numerous other agents, including cyclobenzaprine, gabapentinoids, NMDA antagonists, cannabinoids, and sodium oxybate, have been evaluated, but most remain investigational or limited by safety concerns. Current guidelines emphasize that pharmacological interventions alone are insufficient and should be integrated with non-pharmacological strategies, especially patient education, exercise, and psychological support. This review summarizes the evidence on available and emerging pharmacological options for FM, highlights their limitations, and underscores the need for individualized, multimodal treatment strategies to improve patient outcomes and quality of life.


  • Open Access

    Two Neuroanatomical Subtypes in Fibromyalgia Patients: Distinct Morphological Patterns and Treatment Outcomes

    by Shiya Wu, Bin Jing, Yidan Wang, Meijuan Long, Yanting Li, Zihao Li, Juan Jiao

    Objectives: To better investigate neurobiological heterogeneity in fibromyalgia for its symptom diversity and individual differences.Methods: We collected structural MRI data and clinical characteristics of Chinese female fibromyalgia patients and healthy controls matched by age and educational level, then invited qualified patients to undergo either Ba‐Duan‐Jin or pregabalin intervention for 12 weeks randomly. Structural MRI was analyzed by CAT12 software, and the regional volume of gray matter (GMV) was calculated according to the Brainnetome atlas. Fibromyalgia patients were clustered using the HYDRA algorithm to detect disease subtypes.Results: Two distinct neuroanatomical subtypes were found among 75 patients. Compared to 93 healthy controls, patients in subtype 1 (n = 38, 50.7%) showed widespread GMV increase, especially in some pain‐related brain regions, while no structural changes were observed in subtype 2 (n = 37, 49.3%). At the baseline before treatment, patients in subtype 1 showed a younger age (p = 0.037), longer illness duration (p = 0.042), and a severer psychological stress state evaluated by the Perceived Stress Scale (p = 0.008). After standardized treatment, subtype 1 patients showed less improvement in pain VAS score (p = 0.027) than subtype 2 patients. In addition, GMV of the bilateral dorsal caudate had negative correlations with stress level (Left r = −0.335, p = 0.040; Right r = −0.341, p = 0.036), and GMV of the left rostral temporal thalamus (r = 0.781, p = 0.038) and lateral amygdala (r = 0.761, p = 0.047) were positively related to the improvement of pain severity after treatment in subtype 1 patients.Conclusions: These two neuroanatomical subtypes in fibromyalgia emphasize different underlying neuropathological processes and need future studies to optimize individualized treatment.Trial Registration: ClinicalTrials.gov identifier: NCT03890133


  • Open Access

    Identification of diagnostic biomarkers for fibromyalgia using gene expression analysis and machine learning

    by Fuyu Zhao, Jianan Zhao, Yang Li, Chenyang Song, Yaxin Cheng, Yunshen Li, Shiya Wu, Bingheng He, Juan Jiao, Cen Chang

    Objective: Fibromyalgia (FM) is a complex autoimmune disorder characterized by widespread pain and fatigue, with significant diagnostic challenges due to the absence of specific biomarkers. This study aims to identify and validate potential genetic markers for FM to facilitate earlier diagnosis and intervention.Methods: We analyzed gene expression data from the Gene Expression Omnibus (GEO) to identify differentially expressed genes (DEGs) associated with FM. Comprehensive enrichment analyses, including Gene Ontology (GO), the Kyoto Encyclopedia of Genes and Genomes (KEGG), and Reactome pathways, were performed to elucidate the biological functions and disease associations of the candidate genes. We used the eXtreme Gradient Boosting (XGBoost) algorithm to develop a diagnostic model, which was validated using independent datasets.Results: Three genes, namely, dual-specificity tyrosine phosphorylation-regulated kinase 3 (DYRK3), regulator of G protein signaling 17 (RGS17), and Rho guanine nucleotide exchange factor 37 (ARHGEF37), were identified as key biomarkers for FM. These genes are implicated in critical processes such as ion homeostasis, cell signaling, and neurobiological functions, which are perturbed in FM. The diagnostic model demonstrated robust performance, with an area under the curve (AUC) of 0.8338 in the training set and 0.8178 in the validation set, indicating its potential utility in clinical settings.Conclusion: The study successfully identifies three diagnostic biomarkers for FM, supported by both bioinformatics analysis and machine learning models. These findings could significantly improve diagnostic accuracy for FM, leading to better patient management and treatment outcomes.


  • Warm acupuncture for fibromyalgia with increased cold sensitivity: a cross-over randomised controlled trial

    by Yang Li, Yi Dan Wang, Zi Hao Li, Shi Ya Wu, Meijuan Long, Juan Jiao

    Full Papers; Authors: Y. Li, Y.D. Wang, Z.H. Li, S.Y. Wu, M. Long, J. Jiao


  • Open Access

    Quality of life, pain, depression, fatigue and sleep in patients with remission or mild fibromyalgia: a comparison with remission or low disease activity rheumatoid arthritis and healthy controls

    by Yidan Wang, Pengxiao Liu, Zihao Li, Shiya Wu, Meijuan Long, Yang Li, Juan Jiao, Zheng Xie

    Fibromyalgia is a chronic condition marked by widespread pain and various accompanying symptoms. Compared to healthy individuals and other rheumatic disease patients, it leads to more severe symptoms and a lower quality of life. Whether fibromyalgia patients in a mild activity or remission stage still experience core symptoms remains unclear. To compare the severity of clinical symptoms and quality of life (QOL) in patients with remission or mild fibromyalgia (RFM) and remission or low disease activity in rheumatoid arthritis (RRA) patients and healthy controls (HCs) to investigate whether fibromyalgia in a stable stage can be disease-free. This cross-sectional study evaluated a total of 266 RFM and 252 RRA patients and 50 HCs using Revised Fibromyalgia Impact Questionnaire (FIQR), Widespread Pain Index (WPI), Pain Visual Analogue Scale (VAS), Numerical Rating Scale, Multidimensional Fatigue Inventory (MFI-20), Pittsburgh Sleep Quality Index (PSQI), and Beck Depression Inventory (BDI), and Short Form-36 Health Status Questionnaire (SF-36). The FIQR total score and pain VAS, MFI, and PSQI scores were higher in RFM and RRA patients compared to HCs (P < 0.001). RFM patients had higher BDI and WPI scores than RRA patients (P < 0.001). The majority of RFM patients (97.4%) had more than two pain sites, with moderate-to-severe pain (78.2%), sleep disorders (85.0%), and depression (53.4%), all of which were significantly higher than those in RRA patients (P < 0.001). RFM patients also had lower scores in SF-36 physical and mental component summaries and subscores for role physical, pain index, general health perception, vitality, and mental health index, but a higher social functioning score than RRA patients (P < 0.001). Despite being in a mild activity or remission stage, RFM patients experience more severe symptoms and poorer QOL than RRA patients. Therefore, individualized evaluation and intensive management are required. ClinicalTrials.gov Identifier: NCT02449395, registered on May 20, 2015.


  • Open Access

    Therapeutic efficacy of Roujin formula in managing fibromyalgia patients with liver depression and spleen deficiency syndrome: A single-blinded randomized controlled trial

    by Jingsi Fu, Shiya Wu, Quan Jiang, Juan Jiao

    Objective: Fibromyalgia syndrome (FMS) is a chronic pain condition characterized by central sensitivity to pain, and it is universally acknowledged as a recalcitrant disease. A single-blind randomized controlled trial was conducted to assess the effectiveness and safety of the Roujin formula in treating FMS patients with liver depression and spleen deficiency syndrome, aiming to provide more scientific and effective treatment options. Methods: Forty-eight eligible participants were enrolled and randomly assigned to either the Roujin formula group (n = 24) or the placebo group (n = 24). The Roujin formula group received 150 mL of the Roujin formula twice daily, whereas the placebo group was given a tenth of the Roujin formula dosage, twice daily. The treatment lasted for 8 weeks, with a follow-up extending to 12 weeks. The primary outcome was the improvement in the pain Visual Analogue Scale (VAS) score, whereas secondary outcomes included enhancements in the Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory-II (BDI-II), Revised Fibromyalgia Impact Questionnaire (FIQR), and 36-item Short-Form Health Survey (SF-36) scores. These measures were assessed at baseline and after 4, 8, and 12 weeks. The Patients’ Global Impression of Change (PGIC) was collected at week 12. Safety assessments were based on routine blood tests, urine tests, and liver and kidney function evaluations. Results: The improvement in the pain VAS score was significantly greater in the Roujin formula group than that in the placebo group at the 4-, 8-, and 12-week follow-ups (p < 0.05). At the 8-week treatment and the 12-week follow-up, improvements in PSQI and FIQR scores were also superior in the Roujin formula group compared with the placebo group (p < 0.05). There were no differences between the 2 groups in the improvement of BDI-II scores, SF-36 physical component summary, and mental component summary scores at any observation time points. At the 12-week follow-up, PGIC ratings were significantly better in the Roujin formula group (p < 0.05). There were 4 adverse events, all of which occurred in the Roujin formula group, including 3 cases of diarrhea and 1 case of stomach pain; no serious adverse events were reported during the study. Conclusion: The Roujin formula can effectively enhance the overall condition of FMS patients, relieve pain, improve sleep quality, and elevate physical and mental well-being. Only mild gastrointestinal reactions were observed. The Roujin formula may be a viable candidate for clinical implementation.


  • Open Access

    Validation of the 2011 and 2016 American college of rheumatology diagnostic criteria for fibromyalgia in a Chinese population

    by Juan Jiao, Zeng-Yu Cheng, Yu-Ya Xiao, Hui Wang, Yong-Feng Zhang, Ya-Yun Zhao, Yuan Jia

    To provide a foundation for clinical diagnosis, epidemiological investigation and intervention trials, we examined the reliability and validity of the American College of Rheumatology (ACR) 2011 and 2016 survey diagnostic criteria among Chinese patients based on the fibromyalgia severity (FS) scale. In this study, 200 fibromyalgia patients diagnosed according to the 1990 criteria (1990c) were matched with rheumatoid arthritis (RA) patients based on age and gender. The FS scale score and its subscales were examined to determine their correlations with the revised fibromyalgia impact questionnaire (FIQR). Receiver operator characteristic (ROC) analysis was performed, and test-retest reliability, internal consistency, and construct validity were examined. The area under the curve (AUC) for the ACR 2011c and 2016c was 0.870 and 0.845, respectively, and the sensitivity and specificity were 78.0% and 96.0% for the 2011c and 70.5% and 98.5% for the 2016c, respectively. The FS scale and its subscales were confirmed to exhibit good internal consistency, and they were significantly correlated with the FIQR, thereby indicating adequate construct validity. Using a lower cutoff value 11 points for the FS scale score based on the generalized pain requirement might be a more effective approach in the Chinese population; this approach yielded an AUC of 0.923 and a sensitivity of 87.0% and specificity of 97.5%. The 2011c and 2016c are reliable instruments for diagnosing fibromyalgia patients in China. The FS scale could be a valid tool to assist in fibromyalgia diagnosis, and a cutoff value 11 points is more suitable in Chinese patients. ClinicalTrials.gov ID: NCT03381131.


  • Fibromyalgia in China: sleep quality is related to symptoms, quality of life and especially mental health

    by Yang Li, Meijuan Long, Yidan Wang, Yanting Li, Zihao Li, Juan Jiao

    Full Papers; Authors: Y. Li, M. Long, Y. Wang, Y. Li, Z. Li, J. Jiao


  • A Chinese version of the revised Fibromyalgia Impact Questionnaire: A validation study

    by Yan‐Ting Li, Quan Jiang, Yuan Jia, Yong‐Feng Zhang, Yu‐Ya Xiao, Hui Wang, Ya‐Yun Zhao, Juan Jiao

    Objective: The revised Fibromyalgia Impact Questionnaire (FIQR) was developed to measure the quality of life of patients with fibromyalgia in randomized controlled trials and routine care. The purpose of this study was to translate and adapt the FIQR from English to Chinese, and to examine the validity and reliability of the Chinese version of the FIQR (CFIQR).Methods: Following the translation of the FIQR, fibromyalgia patients from 6 centers were recruited and completed the CFIQR, the validated Chinese version of the Medical Outcome Study Short Form 36 Health Survey (SF‐36) and the Beck Depression Inventory (BDI). In this study, Cronbach's alpha coefficient, test–retest reliability and item total correlation were used for evaluating external and internal reliability; and criterion and structural validity were evaluated.Results: A total of 200 fibromyalgia patients completed the study. The internal consistency was excellent (Cronbach's alpha .90, .88, .88 and .93 for function, overall impact, symptoms scales and total score, respectively; item‐total correlations from .25 to .83.) Test–retest reliability levels of the CFIQR total and subscale scores were strong correlation (intraclass correlation coefficient >0.75). Furthermore, there were significant correlations between the 3 subscale and the total score of the CFIQR and the SF‐36, as well as the CFIQR and the BDI, by criterion validity (P < .01). Confirmatory factor analysis gave an acceptable value for structural validity according to the 3‐factor structures of function, overall impact and symptoms.Conclusions: The CFIQR is a valid and reliable instrument for both clinical practice and research purposes with Chinese speakers globally. [ClinicalTrials.gov: NCT03381131].